Prescription medicine
Ranibizumab Brand names: Cimerli, Lucentis, Byooviz, Nufymco, Susvimo
Ranibizumab (Lucentis) is a prescription medicine with an FDA approval on record since 2006. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the ranibizumab FDA label on DailyMed (effective November 21, 2025, Genentech, Inc.); the BLA 125156 record on Drugs@FDA; every ranibizumab label on DailyMed.
Highlights of the record
FDA label of November 21, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageLUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 )
Forms and strengths
- 0.3 mg/.05ml
- 0.5 mg/.05ml
- 6 mg/ml
- 10 mg/ml
- 100 mg/ml
Injection (solution).
On the market
- Earliest approval on file
- June 30, 2006 Lucentis, Genentech; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 6 of which 0 under generic applications, 6 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2012 0 Class I among all firms' recalls; latest October 18, 2022; 1 more by firms not listed as its makers
- FAERS reports
- 26,592 through July 30, 2026
What is ranibizumab used for?
From the label: indications and usageLUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) Myopic Choroidal Neovascularization (mCNV) ( 1.5 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) 1.5 Myopic Choroidal Neovascularization (mCNV)
FDA pharmacologic class: Vascular Endothelial Growth Factor Inhibitor.
Source: FDA drug label (LUCENTIS), Genentech, Inc., effective November 21, 2025 (SPL set de4e66cc-ca05-4dc9-8262-e00e9b41c36d), via openFDA; the full label on DailyMed
What does the patient leaflet for ranibizumab say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about SUSVIMO?SUSVIMO (ranibizumab injection) is delivered into the eye using the SUSVIMO implant. The SUSVIMO implant and the procedures to insert, fill, refill and remove the eye (ocular) implant can cause serious side effects including: an eye infection (endophthalmitis). Endophthalmitis is an infection of the eyeball that can cause permanent damage to your eye including blindness. Call your healthcare provider right away if you have increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye. Endophthalmitis requires urgent (same day) medical or surgical treatment. a missing layer on top of the white part of the eye (conjunctival erosion). Conjunctival erosion is an area that becomes missing (defect) in the layer (conjunctiva) that covers the white part of the eye which may result in exposure of the implant. Call your healthcare provider right away if you have a sudden feeling that something is in your eye, if you have eye discharge, or watering of the eye. Conjunctival erosion may require surgical treatment. an opening of the layer that covers the white part of the eye (conjunctival retraction). Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye which may cause the implant to be exposed. Call your healthcare provider right away if you have a sudden feeling that something is in your eye, if you have eye discharge, or watering of the eye. Conjunctival retraction may require surgical treatment. See " What are the possible side effects of SUSVIMO? " for other serious side effects that may happen while in treatment with SUSVIMO. To help prevent or keep these side effects from becoming more serious follow all post-procedure instructions your healthcare provider gives you. […]
From the patient leaflet: What should I avoid while receiving SUSVIMO?Do not drive or use machinery until the eye shield can be removed and you can see. Avoid rubbing your eye or touching the area of your eye where the implant is located as much as possible while the implant is in place. If you have to rub or touch your eye, wash your hands first.
Source: FDA drug label (Susvimo), Genentech, Inc., effective November 21, 2025 (SPL set 9c6d9e2a-9a77-4d11-b692-de87cfde3444), via openFDA; the full label on DailyMed
Is there a generic for ranibizumab (Lucentis)?
No generic ranibizumab is approved (Drugs@FDA, October 8, 2026).
- 2006 earliest approval on file
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
Has ranibizumab been recalled?
The FDA's Enforcement Report lists 2 recalls naming ranibizumab since 2012: 0 Class I (the most serious), 1 Class II, 1 Class III; 0 still ongoing. 1 of them is by a firm that FDA's NDC Directory does not list as a maker of ranibizumab and that holds no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| October 18, 2022 | Class III | Genentech Inc | Defective Delivery System: Commercial implants do not meet the filed specification for the intended use, a few patients have experienced an issue with the … |
| May 21, 2012 | Class II | Franck's Lab Inc., d.b.a. Franck's Compounding Lab not a listed maker | Lack of Assurance of Sterility: Franck's Lab Inc. initiated a recall of all Sterile Human Drugs distributed between 11/21/2011 and 05/21/2012. … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the ranibizumab label say about other medicines?
The ranibizumab label names 2 other medicines in its interaction, contraindication or warning sections. The labels of 2 other medicines name ranibizumab. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | warnings and precautions | Patients on antithrombotic medication (e.g., oral anticoagulants, aspirin, nonsteroidal anti-inflammatory drugs) may be at increased risk of vitreous hemorrhage. |
| Verteporfin | warnings and precautions | In a pooled analysis of 2-year controlled studies [AMD-1, AMD-2, and a study of LUCENTIS used adjunctively with verteporfin photodynamic therapy (PDT)], the stroke rate (including both ischemic and hemorrhagic stroke) was 2.7% (13 of 484) in patients treated with 0.5 mg LUCENTIS compared to 1.1% (5 of 435) in patients … |
Source: FDA drug label (LUCENTIS), Genentech, Inc., effective November 21, 2025 (SPL set de4e66cc-ca05-4dc9-8262-e00e9b41c36d), via openFDA; the full label on DailyMed
What do FAERS reports show for ranibizumab?
The FDA Adverse Event Reporting System holds 26,592 reports that list ranibizumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 5,107 are coded as a death and 4,805 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other vascular endothelial growth factor inhibitors
- the pharmacologic class, with prices and generics
- Ranibizumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other